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Abstract Lactic acid bacteria (LAB) are a diverse group of
Gram-positive, nonsporulating, low G+C content bacteria.
Many of them have been given generally regarded as safe
status. Over the past two decades, intensive genetic and mo-
lecular research carried out on LAB, mainly Lactococcus
lactis and some species of the Lactobacillus genus, has re-
vealed new, potential biomedical LAB applications, including
the use of LAB as adjuvants, immunostimulators, or therapeu-
tic drug delivery systems, or as factories to produce therapeu-
tic molecules. LAB enable immunization via the mucosal
route, which increases effectiveness against pathogens that
use the mucosa as the major route of entry into the human
body. In this review, we concentrate on the encouraging ap-
plication of Lactococcus and Lactobacillus genera for the de-
velopment of live mucosal vaccines. First, we present the
progress that has recently beenmade in the field of developing
tools for LAB genetic manipulations, which has resulted in the
successful expression of many bacterial, parasitic, and viral
antigens in LAB strains. Next, we discuss the factors influenc-
ing the efficacy of the constructed vaccine prototypes that
have been tested in various animal models. Apart from the
research focused on an application of live LABs as carriers
of foreign antigens, a lot of work has been recently done on the
potential usage of nonliving, nonrecombinant L. lactis desig-
nated as Gram-positive enhancer matrix (GEM), as a delivery
system for mucosal vaccination. The advantages and disad-
vantages of both strategies are also presented.
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Characteristics of lactic acid bacteria
Lactic acid bacteria (LAB) are Gram-positive, nonsporulating
bacteria, with low-GC content genomes. This group is distin-
guished by the ability to carry out fermentation of carbohy-
drates to form lactic acid. This group of microorganisms in-
cludes cocci and bacilli, representatives of the species belong-
ing to the genera of Lactococcus , Lactobacillus ,
Streptococcus, Pediococcus, Leuconostoc, Bifidobacterium,
and several others. Many LAB have received generally
regarded as safe (GRAS) status from the American Food
and Drug Administration (FDA), but it is worthwhile to men-
tion that pathogenic bacteria such as Streptococcus pyogenes
and Streptococcus pneumonia also belong to this group
(Daniel et al. 2011). Bacteria from the LAB group are charac-
terized by the absence of genes in their genomes that code for
proteins involved in various biosynthesis pathways.
Accordingly, these auxotrophic organisms occur in environ-
ments rich in amino acids, purines, and pyrimidines, where
their high nutritional requirements can be met.
Until recently, bacteria from the LAB group have mainly
been used in the production and preservation of foods. Some
species are recognized as probiotics, which—according to the
definition proposed by the World Health Organization
(WHO)—confer a health benefit on the host when adminis-
tered in adequate amounts (de Vos 2011; FAO/WHO 2001).
However, LAB strains recognized as probiotics differ in their
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activities. Some bacteria of this group modulate the composi-
tion of the bacterial flora of the intestine and thereby maintain
homeostasis of the intestinal microbiota. In addition, several
of probiotics strains stimulate the immune system and reduce
the risk of allergic reactions. Other bacterial species provide
protection against pathogenic bacteria by competing with
them for the colonized surface, by producing compounds that
inhibit the growth of pathogens, or by inducing the production
of mucus and antimicrobial peptides (AMP) by the mucosal
epithelial cells (Isolauri et al. 2004). Probiotic strains are of
utmost importance in supporting the treatment of diseases of
the digestive system (mainly diarrhea of viral etiology or di-
arrhea associated with the use of antibiotics), inflammatory
bowel disease (IBD), and autoimmune disorders (Fontana
et al. 2013; Isolauri et al. 2004).
For more than 20 years, LAB have been intensively studied
as potential bacterial carriers of compounds with therapeutic
or prophylactic effects (Bermudez-Humaran et al. 2011). LAB
enable immunization via the mucosal route, which is not only
simpler than the standard injections but also increases the
effectiveness against pathogens that use the mucosa as their
major route of entry into the human body. Delivery of antigens
using LAB strains may induce both mucosal (sIgA) and sys-
temic immune responses (Bermudez-Humaran et al. 2011).
The attractiveness of LAB in immunoprophylaxis and therapy
is also determined by their resistance to the low pH of gastric
juice and, for certain strains, the ability to adhere to the surface
of the intestinal epithelium.Moreover, some LAB strains have
adjuvant properties, which means that they can enhance the
immune response induced by the carried antigen. Thanks to
the possibility of lyophilization, LAB do not require storage at
low temperature, and administration of the preparation does
not require specialized personnel.
All of these characteristics, in particular, the health-
promoting properties and a high degree of safety of LAB,
make them an attractive alternative to other vectors used for
the construction of vaccines, including attenuated strains of
various species of pathogenic microorganisms, liposomes,
and microparticles. This review examines the progress in
using LAB for immunoprophylaxis.
Genetic engineering tools used for cloning heterologous
genes in Lactococcus lactis
So far, L. lactis remains the model microorganism in LAB
research. Rapid research progress on the use of LAB for treat-
ment and prophylaxis occurred at the turn of the twenty-first
century. In these studies, plasmid-cured strains of L. lactis
subsp. lactis IL1403 and L. lactis subsp. cremoris MG1363,
whose genomes were sequenced in 1999/2001 and 2007, re-
spectively, are most commonly used (Bolotin et al. 2001;
Wegmann et al. 2007; Linares et al. 2010). Currently,
databases provide genetic information on 33 strains of the
species L. lactis (http://www.ncbi.nlm.nih.gov/genome/
genomes/156, November 2014). The first vectors for cloning
foreign genes in LAB were developed about 30 years ago, on
the basis of the replication systems of the two cryptic, broad
host-range plasmids of L. lactis: pWV01 and pSH71 (de Vos
1987; Kok et al. 1984). To date, many derivatives of these
plasmids have been created (Shareck et al. 2004). Another
widely used replicon is pAMbeta-1, isolated from
Enterococcus faecalis. On the basis of its replication system,
the low-copy plasmid pIL252 and the high-copy plasmid
pIL253 were constructed (Simon and Chopin 1988; Shareck
et al. 2004). A number of different systems for the expression
of genes encoding heterologous proteins in the cells of L.
lactis were developed using both constitutive and inducible
promoters. The most commonly used system for expression of
heterologous proteins is the NICE system, utilizing the nisin
promoter (Mierau and Kleerebezem 2005). Many of the de-
veloped expression systems have inducible promoters whose
expression depends on environmental conditions. These in-
clude, for example, the P170 promoter, active at low pH and
subject to self-induction by accumulated lactic acid when the
culture enters the stationary phase of growth (Madsen et al.
1999), or the zit operon promoter that is regulated by ZitR
protein and is activated by low concentration of zinc ions
(the so-called zinc hunger) (Llull and Poquet 2004). The re-
cently described Zirex system enables induction of genes reg-
ulated by the concentration of zinc ions and by the use of the
pneumococci regulatory protein SczA (Mu et al. 2013). In
studies aimed at examining the potential application of LAB
in immunoprophylaxis, promoters induced under conditions
prevailing in the immunized body are particularly useful. One
such expression system is stress inducible controlled expres-
sion system (SICE). The SICE system uses a promoter of the
L. lactis groESL operon, whose expression is induced under
stress conditions (Benbouziane et al. 2013).
Genetic engineering tools used for cloning heterologous
genes in Lactobacillus spp.
In recent years, interest in bacteria of the genus Lactobacillus
has also increased. More than 180 species are included in this
genus (http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/
wwwtax.cgi?id=1578, August 2014). However, most
attention is focused on the strains with proven probiotic
properties; among these are the following bacterial species:
Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus
bulgaricus, Lactobacillus salivarius, Lactobacillus
plantarum, Lactobacillus acidophilus, Lactobacillus
helveticus, and Lactobacillus gasseri (Fontana et al. 2013).
Preparation of expression vectors for gene cloning in cells
of the genus Lactobacillus is challenging, mainly due to the
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unusually high level of genetic diversity. Some of the plasmid
replication systems described are only active in specific
strains, and known lactobacilli promoters have different activ-
ity levels, depending on the strain they are in. The most com-
monly used cloning vectors for L. plantarum, L. acidophilus,
and L. gasseri are those having the replication system of
pWV01, pSH71, or pAMbeta-1 (Stoeker et al. 2011; Bron
et al. 2004b; Duong et al. 2011; Kajikawa et al. 2011, 2012).
In the expression vectors for Lactobacillus, both constitu-
tive promoters—such as Ppgm (phosphoglycerate mutase pro-
moter), Pldhl (lactate dehydrogenase promoter), or PslpA (pro-
moter of the gene encoding the S-layer of the protein SlpA)—
and inducible promoters are used. One of them is the promoter
of a gene coding for a heat shock protein from Enterococcus
faecium; its activity has been analyzed in cells of L. plantarum
(Maidin et al. 2014). Recent global analysis of lactobacilli
transcriptomes, or the investigation of genome libraries using
various reporter genes, has resulted in identification of pro-
moters induced by specific environmental conditions. An
analysis of the transcriptome of L. acidophilus identified pro-
moters that are induced by the presence of carbohydrates, i.e.,
PFOS (fructo-oligosaccharide), Plac (lactose), and Ptre (treha-
lose), but are repressed in the presence of glucose. PFOS may
p rove to be pa r t i c u l a r l y u se f u l i n t h e r apy o r
immunoprophylaxis, as fructo-oligosaccharides are prebiotics
that stimulate the development of the intestinal microflora
(Duong et al. 2011). Using a gene encoding alanine racemase
as a promoter probe for the genome-wide identification of
inducible L. plantarum genes resulted in identification of
many genes whose expression is induced by high salt concen-
tration or by bile salts (Bron et al. 2004a, c).
LAB as carriers of heterologous bacterial, parasitic,
and viral antigens
LAB are characterized by their high physiological and genetic
diversity. Thus, the abilities of different strains to persist and
multiply in an immunized organism differ substantially.
Moreover, dissimilarities in the composition of their cell walls
results in significant differences in the stimulated immune
response. Some cell-wall components such as peptidoglycan,
lipoproteins, or lipoteichoic acids are recognized by eukaryot-
ic Toll-like (TLR) or nucleotide oligomerization domain
(NOD) receptors involved in the anti-inflammatory immune
response. Strain-specific effects of LAB result from the induc-
tion of diverse immune regulatory pathways (Zeuthen et al.
2008; Macho Fernandez et al. 2011). Therefore, the immuni-
zation schedule developed for vaccines that have been gener-
ated on the basis of one member of the LAB group as an
antigen carrier is often unsuitable for immunization of differ-
ent host targets. The data obtained by different research
groups are not consistent, and the difficulties comparing them
result from the use of different antigens, vectors, and immu-
nization schedules. Parameters affecting the immune response
induced by prototypes of LAB vaccines will be discussed in a
later part of this subsection.
Routes of administration
The first use of LAB as a vaccine vector is a 1990 report of
using formalin-killed Streptococcus lactis cells that produced
PAc protein (antigen I/II) on the cell surface to immunize
against Streptococcus mutans. Intragastric immunization of
mice resulted in the production of specific IgG and IgA anti-
bodies; thus, it was shown, for the first time, that LAB could
be an attractive alternative to conventional bacterial carriers of
foreign antigens (Iwaki et al. 1990).
Most of the prototype vaccines using LAB strains as car-
riers addressed infectious diseases caused by human patho-
gens that penetrate through the mucous membranes of the
gastrointestinal, respiratory, and urogenital tracts. For this rea-
son, different routes of administration were examined. For
example, in the case of S. pneumoniae, the efficacy of intra-
nasally administered vaccines was evaluated (Hanniffy et al.
2007), whereas in the case of Helicobacter pylori, oral or
intragastric vaccines were the first to be analyzed (Li et al.
2014). Because the mucosa-associated lymphoid tissue
(MALT) mucous-membrane immune system constitutes one
network covering the whole body, and because lymphocytes
are able to migrate, oral immunization also provides systemic
immunity expressed by the mucous membranes of other or-
gans. LAB strains, acting as carriers of S. pneumoniae anti-
gens, have already been shown to be effective at intranasal
immunization (see below). Thus, based on actual knowledge
about MALT functioning, an L. lactis strain, comprising the
pppA gene of S. pneumoniae expressed from a nisin-inducible
promoter, was also employed for oral immunization of adult,
as well as young, mice. Both the induction of specific anti-
bodies in the gut and the stimulation of a systemic immune
response (IgG in the serum) were observed. This immuniza-
tion raised the resistance of mice to infection, although the
effect was dependent on the serotype of the strain used in
the protective experiment (Villena et al. 2008, 2010).
Carrier strains
Many studies on the effectiveness of various representatives
of the LAB group as carriers of heterologous antigens for
vaccination were conducted with the highly immunogenic tet-
anus toxin C-terminal fragment (TTFC) as antigen. This pro-
tein fragment has been intensively studied as a replacement
for inactivated toxin in the combined diphtheria, tetanus, and
pertussis (DTP) vaccine. The antigen was produced in the
cells of several species of bacteria from the LAB group
(L. lactis, Lactobacillus spp., and Streptococcus gordonii) that
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differ in their ability to survive in colonized ecological niches.
Studies with L. lactis and L. plantarum as TTFC carriers in-
dicated that the immunogenicity of L. lactis was significantly
lower than that of L. plantarum, particularly when those
strains had a mutation in the alr gene encoding alanine
racemase, an enzyme involved in cell-wall synthesis.
Intestinal TTFC-specific immunoglobulin Awas induced only
after immunization with the recombinant L. plantarummutant
strain. This conclusion, however, was not unequivocal be-
cause the gene encoding TTFC was expressed in the LAB
carriers from promoters that are difficult to compare (a nisin-
inducible promoter and a constitutive promoter) (Grangette
et al. 2004).
The effect of the carrier on the level of immune response
was also analyzed with respect to the efficacy of a potential
antimalaria vaccine. Strains producing the well-characterized
merozoite surface antigen (MSA2), a surface protein of
Plasmodium falciparum, were tested, using a number of var-
iants. The antigen produced in the cells of L. lactis, L. reuteri,
and L. salivariuswas associated with peptidoglycan of the live
cells by either covalent or noncovalent binding, or was located
on the surface of cells treated with trichloroacetic acid (TCA).
In addition, genetically different mouse lines were used in the
studies. The combined nasal and oral immunization was
employed in this work. Significant differences in the levels
of induction and the types of induced immune response were
observed, depending on the type of animal immunized, the
genus of the carrier, and the location of the antigen
(Moorthy and Ramasamy 2007). L. lactis and L. plantarum
(alr−) strains expressing the H. pylori B-subunit of urease
(UreB) were also analyzed for anti-Helicobacter immuniza-
tion. A positive effect (induction of the specific antibodies and
reduction of the level of colonization of mice by H. felis) was
only seen after vaccination with a Lactobacillus strain (Lee
et al. 2001; Corthesy et al. 2005). It is postulated that some
L. lactis strains that reveal high affinity to mucus are promis-
ing candidates for development of a vaccine against bird flu
(Szatraj et al. 2014; Radziwill-Bienkowska et al. 2014).
The impact of the carrier on induction of the immune sys-
tem and the effectiveness of the vaccine prototype were also
analyzed in relation to vaccines against S. pneumoniae. Tests
were mainly carried out in a mouse model after intranasal
immunization. The licensed anti-S. pneumoniae vaccines con-
tain bacterial polysaccharides [polysaccharide vaccine
(PSV)], which in some preparations are conjugated to a carrier
protein (CMR197—inactive mutated diphtheria toxin).
Strains of S. pneumoniae are characterized by a high diversity
of serotypes (more than 90 serotypes have been described so
far), and so vaccines are effective only against those serotypes
whose polysaccharides are included in the formulation. Due to
the multidrug resistance of the S. pneumoniae pathogen and
the different geographic distributions of its serotypes, many
studies are being conducted to develop effective formulations
based on conserved protein antigens. Several protein antigens
[Pneumococcal surface antigen (PsaA), Pneumococcal sur-
face protein (PspA), and Pneumococcal protective protein
(PppA)] produced by Lactobacillus and Lactococcus species
at various cellular locations have been examined as protective
antigens. Extensive information on the potential use of LAB
for anti-S. pneumoniae immunization can be found in the ex-
cellent review by Villena et al. (2011). Preliminary experi-
ments proved that intranasal administration of L. lactis that
produced the intracellular antigen PspA to mice was more
effective than intranasal or subcutaneous immunization with
the purified recombinant protein (Hanniffy et al. 2007). The
first immunization attempts using an L. casei strain that
contained the pspA gene of S. pneumoniae cloned on a plas-
mid and under the control of an inducible lactose promoter
showed no stimulation of the immune response, probably due
to low levels of the antigen. Therefore, for the comparison of
the immunogenicity of the LAB strains carrying the pspA
gene, a strong constitutive promoter was employed. Among
the four species tested (L. lactis, L. casei, L. plantarum, and
L. helveticus), used for nasal mice immunization, the lowest
level of immune response was seen for L. lactis, which corre-
lated with a low level of produced antigen and a short nasal
mucosa residence time for the carrier strain. Strains of the
Lactobacillus genus colonized the nasal mucosa for about
3 days and stimulated a significant level of both IgG and
IgA. The studies also indicated differences in the level of
induced immune response between various species of
Lactobacillus genus. The authors suggested that it reflects
differences in their intrinsic adjuvant potential (Oliveira et al.
2006). The adjuvant effect of L. plantarum was also observed
in analysis of the effectiveness of two types of LAB, carriers
of the HPV E7 antigen, as therapeutic cancer vaccines.
Although L. plantarum induced a lesser immune response
than L. lactis, the L. plantarum vaccination resulted in a much
more rapid regression of tumors (Cortes-Perez et al. 2007).
The roles of antigen location and amount
The influence of antigen location, inside or on the surface of
carrier-strain cells, on the efficacy of vaccination has been
tested multiple times. Location—along with the route of ad-
ministration, the immunization schedule, the genus/species of
the carrier strain, and the amount of antigen—is certainly one
of the factors that determines the level and the type of induced
immune response in the host. Research so far yields no clear
answer about the most effective cellular location of the antigen
for immunization.
Foreign proteins in the cytoplasm of LAB, even if they are
secreted by the natural host (e.g., tetanus toxin C-fragment),
typically trigger a satisfactory level of immune response (hu-
moral and cellular) (Grangette et al. 2002; Reveneau et al.
2002). Such localization avoids degradation of antigens by
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proteases present in the gastrointestinal tract, and it alsomakes
them available to the immune system of the host only after
lysis of the carrier strain cells. The release of larger quantities
of cytoplasmic antigen in vivo can be ensured using strains
with a knockout alr gene encoding alanine racemase
(Grangette et al. 2004; Hugentobler et al. 2012a; Corthesy
et al. 2005). The production of large quantities of foreign
protein in the cytoplasm is sometimes lethal to the carrier cells,
or the protein may be intensively degraded. The use of strains
that do not produce exo- or intracellular proteases such as
HtrA and Clp may sometimes allow appropriate production
of heterologous antigen (Morello et al. 2008). In some cases,
the only effective strategy is to change the location of the
antigen. Intracellular production of the E7 protein of human
papillomavirus type 16 (HPV-16) resulted in its rapid degra-
dation. The situation was not improved in an L. lactis strain
incapable of producing ClpP protease. Larger quantities of E7
were only obtained by anchoring of the E7 antigen to the cell
wall or releasing it into the environment (Bermudez-Humaran
et al. 2002; Cortes-Perez et al. 2003). Several strategies to
Bsend^ heterologous proteins to the cell surface of LAB
strains or into the environment have been developed. For an-
tigen secretion, the signal sequence of the protein Usp45 (un-
known secreted protein of 45 kDa)—the only L. lactis protein
secreted in significant quantities by L. lactis—is generally
used (van Asseldonk et al. 1990). The Usp45 signal sequence
also led to satisfactory secretion in Lactobacillus species. The
method to increase the efficiency of secretion is to fuse a
nucleotide sequence encoding the antigenic protein to a nu-
cleotide sequence encoding the synthetic peptide LEIS
STCDA (Guimaraes et al. 2006). Insertion of this peptide
potentially affects precursor conformation and thus facilitates
its processing by cytoplasmic secretory chaperones, or it
might optimize the charge balance around the signal cleavage
site to facilitate translocation (Le Loir et al. 1998).
Two strategies are used to present heterologous antigens on
the surface of LAB. The first makes use of the C terminus of
cell-anchored proteins that contain the LPXTG recognition
motif. Covalent cell-wall attachment of fusion proteins carry-
ing this motif depends on the activity of sortase A (SrtA), an
enzyme with transpeptidase activity (Call and Klaenhammer
2013). To date, the LPXTG motifs of the PrtP proteinase of
Lactococcus (Ramasamy et al. 2006), the PrtB proteinase of
L. delbrueckii subsp. bulgaricus (Kim et al. 2008), the M6
protein of S. pyogenes (Dieye et al. 2001; Ribeiro et al.
2002; Wieczorek and Martin 2010), and protein A of
Staphylococcus aureus have been used to ensure surface lo-
calization of different antigens (Steidler et al. 1998b). The
second approach is based on the peptidoglycan-binding (PA)
domain of some lactococcal proteins, such as AcmA, the ma-
jor autolysin of L. lactis (Buist et al. 1997). The PA is located
in the C terminus of AcmA and comprises three LysM motifs,
each with about 45 amino acids, separated by spacer
sequences. After secretion, AcmA is directed to the cell wall
and its C terminus determines its noncovalent binding to the
cell-wall peptidoglycan (Buist et al. 2008). It has been dem-
onstrated that hybrid PA fusions exhibited similar binding
(Bosma et al. 2006; Steen et al. 2003; Raha et al. 2005). In
addition, the LysM domains of other Gram-positive bacteria
bind heterologous proteins to the cell-wall peptidoglycan (Xu
et al. 2011; Turner et al. 2004; Hu et al. 2010). In 2011, lipo-
protein basic membrane protein A (BmpA), a component of
the classic ABC transporter responsible for the import of pu-
rines, was identified (Berlec et al. 2011). BmpA is covalently
anchored to the membrane bilayer. The possibility of using
this protein as a carrier of antigens is currently being examined
(Zadravec et al. 2014).
Determination of the genomic sequence of many LAB
strains has enabled analysis of their proteomes, including the
secretome (the set of proteins forming the cell envelope and
those secreted into the environment). These data may be used
to search for new strategies aimed at manipulating the locali-
zation of foreign antigens in the cells of the carrier.
The first study aimed at determining the significance of
antigen location for immune response induction used the
above-mentioned tetanus toxin C-fragment (TTFC)
(Reveneau et al. 2002). In that work, the authors evaluated
the immunogenicity of recombinant strains of L. plantarum
producing variants of TTFC that went to the cytoplasm, to the
cell wall or to the environment. They also tested three routes
of immunization in mice: subcutaneous, intragastric, or intra-
nasal. The immune responses (specific IgG in serum)
established after subcutaneous application did not depend on
the location of the antigen. In contrast, when administered to
mucosal surfaces of the stomach or nose, the best results were
obtained when the antigen was present in the cytoplasm.
Cytoplasmic production led to the highest production of
TTFC and that was believed to be the cause for the differences
observed. The quantity of antigen in the carrier cells after
intragastric administration is very important. A significant im-
mune response was observed following administration of
L. plantarum containing high amounts of TTFC protein
(Grangette et al. 2002). When lower amounts of the antigen
were present in the cytoplasm, the levels of IgG antibodies
only increased after intranasal administration. Furthermore,
these antibodies did not neutralize the tetanus toxin. A protec-
tive effect was only observed when LAB strains producing
high concentrations of the antigen were administered to the
nasal mucosa, which suggests that the amount of the antigen is
important for inducing antibodies with a high avidity
(Grangette et al. 2001, 2002).
The use of different carrier strains or different routes of
administration often makes it impossible to compare and eval-
uate the significance of antigen localization in the induction of
an immune response. For this reason, the studies of Marelli
et al. on the use of L. lactis as the carrier of the rotaviral VP8
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protein are noteworthy. In mice that were orally immunized
with a L. lactis strain producing the cytoplasmic form of VP8
antigen, significant levels of intestinal IgA antibodies were
observed. But when the VP8 antigen was anchored to the
L. lactis cell wall by S. pyogens M6 protein cell wall anchor
domain, the immune response included both specific sIgA
antibodies throughout the mucus membranes of the gastroin-
testinal tract, as well as induction of IgG antibodies.
Subsequently, the infectious ability of viral particles incubated
with antibodies isolated from the immunized animals was
studied using the MA-104 cell line (fetal monkey kidney cell
line). Antibodies from animals that were immunized using the
L. lactis strain with VP8 protein localized in the envelope
showed 100 % neutralization of the viral particles, whereas
antibodies from animals that were immunized using a strain
with cytoplasmic localization of the antigen showed only
50 % reduction of viral infectivity (Marelli et al. 2011). The
use of VP7 protein, a different rotavirus antigen, provided
contradictory data. Antibodies induced by a form of the pro-
tein anchored in the cell envelope did not neutralize viral
particles. The highest immunogenicity was exhibited by the
L. lactis strain that secreted VP7 protein into the environment
(Perez et al. 2005).
It has also been observed that the type of anchoring motif
on the surface of the antigen-presenting LAB cells may sig-
nificantly affect the efficacy of vaccination (Kajikawa et al.
2011). In the recent literature, the importance of the fate of the
antigen after it is delivered to the immunized organism is also
discussed. For example, an extremely positive effect was ob-
tained by generating a fusion of the protective antigen (PA) of
Bacillus anthracis with a peptide that delivers it to dendritic
cells (DCs) (Mohamadzadeh et al. 2009, 2010). Enhancement
of the immune response was also obtained by coexpression of
a Salmonella enterica gene encoding flagellin, a protein-
stimulating TLR5 receptors, and a gene encoding the Gag
HIV-1 protein in an L. acidophilus strain (Kajikawa et al.
2012).
Comparison of the effectiveness of live LAB strains and GEM
particles
In 2005, a new carrier system was developed using
nongenetically modified LAB (Bosma et al. 2006). When
LAB cells are treated with hot trichloroacetic acid, which de-
prives them of surface lipoteichoic acids, proteins, and the
cytoplasmic content, the peptidoglycan remains intact and
provides a particle shape similar to live cells. The resulting
particles are known as Gram-positive enhancer matrix
(GEMs). The procedure applies the antigen–PA fusion pro-
teins produced and purified from (recombinant) Escherichia
coli or L. lactis, which subsequently are mixed with GEM
particles. GEM particles reveal higher binding ability of fused
proteins containing PA domain than live LAB cells. Thus, this
strategy offers an opportunity to use nongenetically modi-
fied organism (non-GMO) and ready-to-go formulation.
The lack of recombinant DNA in this procedure eliminates
the risk of uncontrolled dissemination of nucleic acids into
the environment. An additional advantage of this strategy is
the stability of GEM particles and the possibility of long-
term storage (Bosma et al. 2006; van Roosmalen et al.
2006). Additionally, it has been recently shown that the
simple mixing the subunit vaccine with the GEM particles
results in a strongly enhanced immune response especially
after intranasal application (see below). Thus, the GEM
particles produced from a bacterium, which is used in the
production of dairy products, are more safe in comparison
to other adjuvants and can be considered as a candidate
adjuvant for mucosal use in humans. However, GEM par-
ticles have one disadvantage compared to using live LAB
strains (Lactobacillus) for immunization. Live strains can
colonize the gut, reducing the number of vaccine doses
needed and significantly simplifying the immunization
procedure.
So far, GEM particles have been tested as carriers to im-
munize against three pathogens: S. pneumoniae [IgA1 prote-
ase (IgA1p), putative proteinase maturation protein A
(PpmA), and streptococcal lipoprotein (SlrA)], Yersinia pestis
(the LcrV protein), and P. falciparum (the merozoite surface
antigen MSA2) (Audouy et al. 2006, 2007; Ramasamy et al.
2006; Ramirez et al. 2010). The immunogenicity and protec-
tive efficacy of L. lactis GEM particles displaying Y. pestis
LcrV was investigated in a neonatal mouse model. Newborn
mice immunized intranasally with GEM-LcrV developed
LcrV-specific antibodies, Th1-type cell mediated immunity,
and were protected against lethal Y. pestis (plague) infection
(Ramirez et al. 2010). GEM presenting MSA2 used to oral
immunizations of rabbits was equally efficient in eliciting
antigen-specific antibody responses as live L. lactis cells pro-
ducing the same antigen (Ramasamy et al. 2006). Intranasal
immunization with GEM particles displaying three pneumo-
coccal antigens (PpmA, SlrA, and IgA1p) showed significant
protection against fatal pneumococcal pneumonia in mice
(Audouy et al. 2006, 2007). It was also demonstrated that
the GEM particles may constitute a platform for presentation
of several antigens at the same time, which may be significant
for immunization against pathogens with a high genetic vari-
ability, such asCampylobacter jejuni, a leading cause of food-
borne gastrointestinal diseases (Kobierecka et al. 2015;
Wyszynska et al. 2004). The results illustrate the potential of
using nongenetically modified L. lactis as a safe vaccine de-
livery vehicle to elicit systemic antibodies, thereby avoiding
the dissemination of recombinant DNA into the environment.
When using GEM particles as a platform for presenting of
heterologous antigens, intranasal immunization is generally
most effective in respect to the induced immune response as
well as to the protective effect.
2972 Appl Microbiol Biotechnol (2015) 99:2967–2977
GEM particles, though devoid of surface proteins, retain
inflammatory properties characteristic of live bacteria
(Audouy et al. 2006, 2007) and have adjuvant properties.
While analyzing the adjuvant properties of GEM particles, a
commercially available, monovalent H3N2 vaccine, contain-
ing hemagglutinin and GEM particles, was administered to
mice intranasally. In contrast to other experiments, the influ-
enza virus antigen was not anchored on the surface of the
GEM particles, but rather constituted a separate component
of the vaccine. While the resulting systemic response (IgG)
was similar to mice vaccinated intramuscularly with influenza
vaccine, the mucosal response (sIgA) was significantly higher
for the intranasal vaccination with GEM particles. An in-
creased number of cells producing IFN-γ was also observed,
which indicates the dominant response of the Th1-type lym-
phocytes (Saluja et al. 2010a). When GEM particles are used
as an adjuvant, the hemagglutinin dose can be reduced up to
fivefold and still induce a protective effect in mice (Saluja
et al. 2010b).
These promising results attracted interest from Mucosis
B.V., a Dutch biotechnology company (mucosis is the first
spin-off of the Biomade Technology Foundation) (Audouy
et al. 2006). A phase I clinical trial of a mucosis influenza
vaccine for human use (FluGEM) is almost finished.
FluGEM is the only vaccine, based on LAB as carriers, to
reach this stage of investigation.
LAB as DNA vaccines
Genetic immunization with plasmid DNA has been studied
for over 20 years, for both immunoprophylaxis of infectious
diseases and also cancer immunotherapy. DNA immunization
leads to the induction of both humoral and cellular immune
responses. Plasmid DNA can be delivered by intramuscular
injection (the so-called naked DNA immunization) or using
suitable bacterial carriers. The intensive studies conducted so
far have focused on the use of attenuated, enteroinvasive bac-
teria, such as Salmonella spp., Yersinia enterocolitica, or
Listeria monocytogenes, as well as appropriately modified
E. coli cells producing O listeriolysine (L. monocytogenes)
and/or invasin (Y. enterocolitica) as DNA carriers (Daudel
et al. 2007; Schoen et al. 2008). Initial studies have shown
that a 3-h incubation of L. lactis MG1363 strain, harboring
plasmid DNA, with CaCo-2 cells, results in the transfer of the
plasmid into the eukaryotic cells and expression of the plas-
mid (Guimaraes et al. 2006). DNA transfer has also been
observed in vivo in mice, after oral administration of the
L. lactis strain producing the tested allergen (BLG protein—
cow β-lactoglobulin). The presence of complementary DNA
(cDNA) and protein production in the cells of the small intes-
tine, and the production of specific IgG and IgA antibodies,
were both reported. The entry mechanism for the blg gene
remains unexplained. There are at least two possibilities: ei-
ther the eukaryotic cells take up plasmid DNA that is released
into the intestine from L. lactis, or L. lactis has been taken up
by the eukaryotic cells (Chatel et al. 2008).
Because LAB are generally thought to be incapable of in-
vading eukaryotic cells, strains were designed to interact with
eukaryotic cells, which would lead to their internalization.
Plasmid DNA transfer into eukaryotic cells has been inten-
sively studied using L. lactis that either extracellularly ex-
presses FnBPA protein (a fibronectin binding protein A of
S. aureus) or InlA (L. monocytogenes internalin). The
above-described blg gene and the gfp gene (encoding green
fluorescence protein) were used as reporter genes (cDNA).
FnBPA, tested both in vitro and in vivo, increased the amount
of DNA of the reporter gene in eukaryotic cells, but did not
increase the quantity of the antigen produced. The data addi-
tionally suggested different mechanisms for in vitro and
in vivo entry (Pontes et al. 2012). Similarly, elevated levels
of invasiveness and delivery of the GFP-coding plasmid were
observed in the in vitro experiment using L. lactis that
expressed the major InlA internalin of L. monocytogenes.
The receptor for internalin A is E-cadherin. Due to the struc-
ture of the various E-cadherins, InlA recognizes human but
not murine E-cadherin. The construction of a L. lactisNZ9000
strain exposed the mutated form of InlA, which binds to mu-
rine E-cadherin, making it possible to carry out in vivo exper-
iments in the murine model. These, like the in vitro experi-
ments, showed increased invasiveness of the strain, though
production of the analyzed protein (BLG) was not increased
in vivo (Innocentin et al. 2009; de Azevedo et al. 2012). The
in vitro analyses above, as well as the data on immunization
against S. pneumonia with pure plasmid DNA, obtained from
in vivo experiments (Ferreira et al. 2006; Vadesilho et al.
2012), suggest a high potential for application the LAB as
DNA vaccines.
Modulation of the activity of the immune system
Cytokines play an important role in cell signaling, transmit-
ting stimuli and directing immune responses. Attempts are
being made to use LAB strains to carry particles that can
control the type of induced immune response, with the main
focus on their use as therapy for inflammatory diseases of the
gastrointestinal tract (Wells and Mercenier 2008). LAB vec-
tors that express antigens of pathogenic microorganisms or
secrete cytokines into the environment should evoke a more
effective immune response. The first studies on using cyto-
kines in immunization with L. lactis involved intranasal ad-
ministration in mice of an L. lactis strain, producing both the
TTFC and biologically active murine cytokines IL-2 or IL-6.
Coproduction induced significantly higher levels of specific
IgG antibodies than when L. lactis produced only TTFC
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(Steidler et al. 1995, 1998a). The use of L. lactis expressing
chicken interleukin 2 (chIL-2) together with avian influenza
hemagglutinin (H5) also revealed adjuvant properties of chIL-
2, and the study suggests that L. lactis could be a promising
candidate as antigen carrier in vaccines against avian flu
(Szatraj et al. 2014). In recent years, the influence of IL-12
on the immune system has been extensively studied. One of
the promising examples of IL-12 in immunoprophylaxis is the
development of a vaccine against leishmaniasis, an infectious
disease caused by Leishmania parasites that kills 50,000 peo-
ple a year worldwide. Two L. lactis strains were developed,
one producing an L. major antigen, LACK, anchored to the
bacterial cell wall, and the second secreting active murine IL-
12. Subcutaneous administration of both strains to mice re-
sulted in a specific Th1 response (Hugentobler et al. 2012b). A
strain capable of simultaneous expression of the LACK anti-
gen and IL-12 evoked an immune response that protected
mice from a subsequent infection by L. major (Hugentobler
et al. 2012a).
Summary
In the two decades since the first reports, many studies of LAB
as vaccine vectors have been published. Most of these used
LAB as carriers of foreign antigens to immunize against path-
ogens that enter the human body through the mucous mem-
branes of the respiratory and digestive tracts. LAB strains
show enormous potential, especially the use of members of
the Lactobacillus genus for immunoprophylaxis. However,
results of the many studies are difficult to compare and inter-
pret due to the high diversity of bacterial physiology and ge-
netics within the LAB group. The LAB are characterized not
only by a varied ability to survive in the intestinal environment
but also by a varied interaction of the bacteria with epithelial
surfaces and lymphatic cells, even among strains of the same
species. In conclusion, it should be emphasized that each po-
tential vaccine that uses LAB as antigen carriers will probably
require different genetic constructs, in terms of the localization
of the antigen in the carrier cell, and different immunization
schedules. Furthermore, the efficacy of these constructs will
only be known through in vitro and in vivo testing. GEM
particles are nonlive and nonrecombinant derivative of
L. lactis. Thus, this strategy eliminates all risks attributable
to GMO application. However, using GEMswill require com-
plicated immunization procedure. They are not effective when
used for oral immunization but efficacious when administered
by intranasal route. On the other hand, so far tested genetically
modified live LAB carriers of heterologous antigens contain
plasmids harboring genes conditioning antibiotics resistance.
Thus, introducing these strains for human or animal vaccina-
tion will require construction of specific host–vector balance
systems in which the chromosomal deletions of housekeeping
genes will be complemented by wild-type copies of genes
present on plasmids. This strategy, which eliminates drug-
resistancemarkers in live vaccines, has been successfully used
in case of other live vaccines. Based on so far published data,
using GEM vs live LAB strains for human immunization will
be determined by the required type of immune response as
well as by the most efficient route of immunization, and it
has to be verified in clinical trials.
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